Claims
- 1. A nebulizer suspension consisting essentially of water, mometasone furoate monohydrate, a nonionic surfactant, about 0.2 to about 2 weight percent of sodium chloride or potassium chloride and, optionally, a pH buffer.
- 2. The suspension of claim 1, wherein mometasone furoate monohydrate comprises about 50 micrograms to about 5 milligrams, per milliliter.
- 3. The suspension of claim 1, wherein the surfactant comprises a Polysorbate surfactant.
- 4. The suspension of claim 1, wherein the surfactant comprises Polysorbate 80.
- 5. The suspension of claim 1, wherein the surfactant comprises a Poloxamer surfactant.
- 6. The suspension of claim 1, wherein the surfactant comprises about 50 micrograms to about 1 milligram, per milliliter.
- 7. The suspension of claim 1, wherein the salt comprises sodium chloride.
- 8. A method for treating airway disorders, comprising administering by nebulization to surfaces of the airway a treatment-effective amount of the suspension of claim 1.
- 9. The suspension of claim 1, which includes a pH buffer.
- 10. The suspension of claim 9, wherein the buffer comprises a citric acid-citrate buffer.
- 11. The suspension of claim 9, wherein the buffer maintains aqueous phase pH values about 3 to about 7.
- 12. The suspension of claim 9, wherein the buffer maintains aqueous phase pH values about 3 to about 6.
- 13. The suspension of claim 9, wherein the buffer maintains aqueous phase pH values about 4 to about 5.
- 14. The suspension of claim 1, wherein solid particles have average sizes less than about 5 μm.
- 15. The suspension of claim 1, wherein solid particles have average sizes less than about 2 μm.
- 16. A process for producing a nebulizer suspension, comprising combining ingredients consisting essentially of water, mometasone furoate monohydrate, a nonionic surfactant, about 0.2 to about 2 weight percent of sodium chloride or potassium chloride and, optionally, a pH buffer and subjecting the combination to particle size reduction by ultrasonication or by jet milling.
- 17. The process of claim 16, wherein the combination includes a pH buffer.
- 18. The process of claim 16, wherein particle size reduction is continued to produce solid particles having sizes less than about 10 μm.
- 19. The process of claim 16, wherein particle size reduction is continued to produce solid particles having average sizes less than about 5 μm.
- 20. The process of claim 16, wherein particle size reduction is continued to produce solid particles having average sizes less than about 2 μm.
- 21. A method for treating airway disorders, comprising administering by nebulization to surfaces of the airway a treatment-effective amount of a suspension prepared by the process of claim 16.
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefits under 35 U.S.C. § 119(e) from provisional application 60/061,633 filed Oct. 9, 1997.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5192528 |
Radhakrishnan et al. |
Mar 1993 |
|
5837699 |
Sequeira et al. |
Nov 1998 |
|
5889015 |
Sequeira et al. |
Mar 1999 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9204365 |
Mar 1992 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/061633 |
Oct 1997 |
US |